Podcasts about ADT

Daniel moderated a live panel at Running Remote 2026 with Carmen Amara (Yelp), Brandon Sammut (Zapier), and Vinícius Coelho (Time Doctor) to discuss how AI is reshaping leadership, management, and career growth. ----  Sponsor Links:

In this compelling episode of the Dr. Geo Prostate Podcast, Dr. Geo sits down with internationally renowned exercise oncology pioneer Professor Robert Newton to explore the groundbreaking science behind exercise as medicine for cancer.Inspired by his father's battle with prostate cancer, Professor Newton has spent decades researching how targeted exercise can improve treatment outcomes, preserve muscle mass, strengthen immune function, reduce treatment side effects, and potentially slow cancer progression. Together, Dr. Geo and Professor Newton discuss why muscle is far more than a movement organ—it functions as a powerful endocrine organ that releases cancer-fighting compounds known as myokines.The conversation dives deep into exercise intensity, resistance training, chemotherapy and radiation timing, wearable technology, exercise "dosing," and the landmark Phase III clinical trial that demonstrated exercise can significantly improve survival outcomes in cancer patients. They also discuss practical strategies for overcoming fear of the gym, maintaining muscle during androgen deprivation therapy (ADT), and why sitting all day may undermine your health even if you exercise regularly.Whether you're living with prostate cancer, supporting a loved one, or simply interested in maximizing your healthspan, this episode provides actionable, science-backed strategies to help you move from surviving to thrivingEpisode Timestamps00:00 Introduction & Guest Welcome 03:00 Rob Newton's Father & Origin Story 09:30 Exercise as the #1 Anti-Cancer Tool 17:00 Landmark Exercise Oncology Trial 20:00 Exercise as Medicine 26:00 Resistance Training Intensity Explained 35:30 Exercise Before Radiation & Chemotherapy 40:00 Exercise Timing Around Treatment 47:00 Myokines: Muscle as Medicine 52:00 NEAT & Daily Movement 58:00 Final Takeaways & Closing ThoughtsResources MentionedMy Exercise Medicine for Cancer by Professor Robert NewtonExercise Medicine Research InstituteNew England Journal of Medicine Exercise Oncology TrialAmerican Society of Clinical Oncology (ASCO) Researc___________________________________

Welcome to this episode of Oncology Brothers, where we dived into the latest advancements in GU malignancies! We welcomed esteemed guests Dr. Brian Rini and Dr. Thomas Powles, both GU medical oncologists and co-hosts of the Uromigos podcast.   In this episode, we discussed key studies presented at ASCO 2026 that are set to change clinical practice in prostate, kidney and bladder cancer, and recent FDA approvals in the GU space: PROTEUS:  trial comparing ADT monotherapy to apalutamide plus ADT in high-risk localized prostate cancer. We explored its findings, implications, and the ongoing debate surrounding its control arm. TALAPRO-3 Study: impact of PARP inhibitors combined with enzalutamide in metastatic castration-sensitive prostate cancer with homologous recombination repair (HRR) mutations. We discussed the nuances of HRR mutations and their clinical significance. CAPITELLO-281: insights into the recent approval of this AKT inhibitor for metastatic castration-sensitive prostate cancer with PTEN loss, based on the CAPItello-281 study. EV-302 update: combination of EV-pembrolizumab still maintains the doubling of survival benefit with longterm follow up. POTOMAC: durvalumab + BCG induction therapy for high-risk non-muscle invasive bladder cancer (NMIBC) could be a choice for a selected patient population. LITESPARK-022: The new approval of belzutifan with pembrolizumab in the adjuvant setting, discussing its efficacy and the importance of patient selection.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o ' Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966   Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/   Throughout the episode, we emphasized the importance of balancing treatment benefits with potential adverse events, as well as the need for shared decision-making in clinical practice. #GUOncology, #ASCO2026, #ProstateCancer, #BladderCancer, #RenalCellCarcinoma, #OncologyBrothers

In this EAU Podcast episode, Ass. Prof. Giancarlo Marra (IT), Prof. Derya Tilki (DE) and Prof. Philip Cornford (IE) discuss the latest updates in the 2026 EAU Guidelines on Prostate Cancer.They explore changes in risk stratification, the evolving role of enzalutamide plus ADT in high-risk disease, and emerging diagnostic technologies such as micro-ultrasound and NeuroSAFE. The conversation also highlights advances in personalised treatment approaches for metastatic hormone-sensitive prostate cancer, including BRCA and PTEN-targeted strategies.In addition, the speakers emphasise the growing importance of supportive care, bone protection, and managing long-term treatment-related side effects to improve patient outcomes.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

Ray'n Terry, Chief People Officer at MOO, joined us on The Modern People Leader to discuss why AI should create more space for humanity at work instead of simply increasing productivity. We talked about balancing business performance with employee wellbeing, rethinking performance management in an AI-powered world, and why leaders must intentionally help people reclaim time, creativity, and connection.----  Sponsor Links:

Amy Reichanadter, Chief People Officer at Databricks, joined us on The Modern People Leader to discuss her upskilling journey throughout her career, creating consumer-grade employee experiences, and leading through rapid technological change. ----  Sponsor Links:

Medicus Pharma Chief Medical Officer Dr Faisal Mehmud joined Steve Darling from Proactive to discuss the company's successful submission of a substantial modification application through the European Union Clinical Trials Information System (CTIS), supporting the planned Phase 2b study of Teverelix® in advanced prostate cancer. Mehmud said the submission marks an important step in advancing Teverelix® toward registrational development, with a particular focus on prostate cancer patients who have elevated cardiovascular risk and require androgen deprivation therapy (ADT). This patient population represents a significant unmet medical need, as cardiovascular complications remain a major consideration in treatment selection and long-term management. The planned Phase 2b study is designed to optimize dose selection and further evaluate the pharmacokinetic, pharmacodynamic, efficacy, and safety profile of Teverelix® ahead of later-stage development. The data generated will help guide future registrational studies and support regulatory discussions in both Europe and the United States. Medicus has already engaged extensively with the U.S. Food and Drug Administration regarding its advanced prostate cancer development strategy, including future clinical programs focused on patients with heightened cardiovascular risk. Subject to regulatory review and approval, the company expects to begin patient enrollment later this year. Results from the study are anticipated to play a key role in determining optimal dosing, refining pivotal trial design, and advancing interactions with global regulatory agencies. Management's objective is to position Teverelix® as a best-in-class hormonal therapy specifically developed for advanced prostate cancer patients where cardiovascular safety is a critical treatment consideration. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #ClinicalTrials #Phase2 #Teverelix #Biotech #DrugDevelopment #FDA #Urology #BPH #AUR #MensHealth #PharmaInnovation #Healthcare #MedicalResearch #Biopharma

Gustavo Guanabara volta ao ADT para comentar o que achou da WWDC26, além das novidades do Google for Brasil 2026.

Dennis Rader was the council president of Christ Lutheran Church in Park City, Kansas, on the morning of February 25, 2005. The Wichita Police Department was, at the same moment, on its way to arrest him. The thing that had identified him as BTK was a metadata trace from a Microsoft Word document he had saved to a church computer in his role as council president.He had volunteered for the council. He had volunteered to print agendas. He had risen through the ranks to council president, the visible layperson at a small congregation. He had been doing both jobs for years. The killing and the church. The Cub Scout pack and the typed letters to the press. The compliance officer truck and the kits in the garage.In the third chapter of host Tony Brueski's five-part Hidden Killers investigation, every official role Dennis Rader chose for himself gets examined for what it actually gave him. The ADT alarm installer job that put him inside hundreds of Wichita homes legally during the most active years of his killing. The Cub Scout pack leader role that put him in front of children while teaching them the family of knots that had been showing up at his crime scenes since 1974. The Lutheran council seat that gave him community standing and, eventually, identified him to investigators. The Sedgwick County Zoning Appeals seat. The Animal Control Advisory Board. The compliance officer truck.This episode also walks through Misty King's story. A Park City divorcee who fled the state with her two children after Dennis Rader, in his city role, made her life unlivable.This is the third uncomfortable truth of the series. Dennis Rader did not hide despite his costumes. He hid inside them.END LINKSJoin Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/ Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/channel/UC8-vxmbhTxxG10sO1izODJg?sub_confirmation=1 Instagram https://www.instagram.com/hiddenkillerspod/ Facebook https://www.facebook.com/hiddenkillerspod/ Tik-Tok https://www.tiktok.com/@hiddenkillerspod X Twitter https://x.com/TrueCrimePodDISCLAIMERThis publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.HASHTAGS#BTK #DennisRader #ChristLutheran #ChurchCouncil #HiddenKillers #TrueCrime #SerialKillers #ParkCity #ColdCase #UncomfortableTruths

Cameron Price, Head of People & Talent at Medium, joined us on The Modern People Leader to discuss how people teams can lead AI change management through trust, curiosity, and human-centered design. We talked about AI fluency, balancing innovation with authenticity, measuring employee sentiment around AI adoption, and why humans-first leadership matters more than ever. ----  Sponsor Links:

For half a century, the BTK Killer story has been told the way Dennis Rader wanted it told. Factor X. The Minotaur. The BTK brand. Every term that has anchored his mythology came from a typewriter in his own kitchen in Park City, Kansas. Every term was his.In this first chapter of a five-part investigation from True Crime Today, host Tony Brueski sets the version of Dennis Rader that documentaries have repeated for forty-seven years next to the actual investigative file. The two don't match.The man who wrote the 1978 Factor X letter to KAKE-TV was a thirty-two-year-old husband and father. An alarm installer for ADT in Wichita. A student at Wichita State University working toward a degree in the administration of justice. He had taken courses on profiling. He knew what serial killers were supposed to sound like in the cultural imagination of the late seventies. He typed himself into the role.The press printed his words. The cops filed his words. The country read his words. And for nearly fifty years, when somebody has tried to explain Dennis Rader, they have explained him the way he wanted to be explained.This episode walks through the 1978 letter sentence by sentence. The literary references he borrowed from. The cultural figures he compared himself to. The contradictions inside the letter that read, in retrospect, less like the confession of a possessed killer and more like the audition tape of a man trying out for a role.The series will continue with the chase that didn't close, the official roles that made him invisible, the thirteen-year silence between his confirmed killings, and the floppy disk that ended his thirty-one years of getting away with it. Start here.END LINKSJoin Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/ Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/channel/UC8-vxmbhTxxG10sO1izODJg?sub_confirmation=1 Instagram https://www.instagram.com/hiddenkillerspod/ Facebook https://www.facebook.com/hiddenkillerspod/ Tik-Tok https://www.tiktok.com/@hiddenkillerspod X Twitter https://x.com/TrueCrimePodDISCLAIMERThis publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.HASHTAGS#BTK #DennisRader #BTKKiller #TrueCrimeToday #FactorX #SerialKillers #Wichita #ParkCity #TrueCrime #ColdCase

Nir Leibovich, Product Executive at QuickBooks Workforce, joined us on The Modern People Leader to discuss why HR and finance teams struggle when data lives in silos and how unified systems create better business decisions. Downloadable PDF with top takeaways: https://modernpeopleleader.kit.com/episode306----  Sponsor Links:

Amy Schwartz, Chief People Officer at Wiz, joined us on The Modern People Leader. We talked about why HR alone can't create a high-performance culture, why relationships and influence matter more than HR systems, and why "picking up the trash" - a leadership philosophy she picked up working in casinos - has stuck with her ever since.----  Sponsor Links:

Breaking News podcast just after the long-awaited PROTEUS trial reads out at the ASCO Plenary in Chicago! Plus a simultaneous NEJM paper! Huge day for prostate cancer surgery. Declan and Renu are joined by lead author Dr Mary-Ellen Taplin (Dana Farber Cancer Institute & Harvard University), to tell us about her decades long journey to this huge moment today. PROTEUS is a huge (2,100 men) phase III RCT of men undergoing radical prostatectomy for high-risk prostate cancer, randomised to receive peri-operative ADT + placebo, or ADT plus apalutamide. Mary-Ellen talks to us about the top-line results, and we consider whether this is truly a practice-changing study. Declan also had the honour of being the Discussant at teh ASCO Plenary so he is well placed to give his opinion. Your usual hosts are Declan Murphy & Renu Eapen. Even better on our YouTube channel This is a Themed Podcast supported by our Gold Partner, Johnson & Johnson.Links:PROTEUS NEJM paper

Laura Tomaino, Chief People Officer at Glooko, joined us on The Modern People Leader. We talked about why “People-First” leadership feels harder in 2026 and what it actually looks like to live up to that today.----  Sponsor Links:

In this episode, Andrew is joined by Jimmy Lin from ADT who shares the insider story behind ADT's new DIY-focused Blu system—an easy-to-install, smart security kit designed for the modern homeowner. We break down how ADT may leverage open standards like Matter and Z-Wave, aiming to unify the smart home ecosystem and finally bridge the gap between security and automation.You'll uncover:How ADT's innovative products like the new Live Light smart sign and color night-vision cameras empower homeowners to be proactive rather than reactive.The role of AI and sensor fusion, like Wi-Fi and activity zone detection, in predicting threats before they happen.Why a focus on privacy, seamless integration, and ease of use is transforming the DIY security market.The strategic move into open protocols to create a more connected, interoperable smart home landscape.What's next for ADT: The possibility of introducing scene automation, smart home triggers, and voice command support like Siri shortcuts to truly integrate security with daily life.Jimmy Lin is VP of Product Management at ADT, steering innovations that bridge the gap between trusted home security and intelligent automation. With extensive experience in consumer electronics and AI-powered products—from GoPro cameras to AR glasses—Jimmy brings a keen eye for transforming classic brands into future-ready powerhouses.This episode is packed with actionable insights and future trends that will shape your smart home strategy. Perfect for tech lovers, security pros, and anyone eager to stay ahead of the curve. Don't miss out—hit play now and discover how ADT is redefining what home security can be.Send me your smart home questions and recommendations with the hashtag #SmartHomeInsider. Tweet and follow your host at:@andrew_osu on Twitter@andrewohara941 on ThreadsEmail me hereSponsored by:Shopify: Sign up for a one-dollar-per-month trial period at shopify.com/homekit!Copilot Money:  Limited-time: Get two months free when you sign up at copilot.money/smarthome and use coupon code SMARTHOME!Smart Home Insider YouTube ChannelSubscribe to the Smart Home Insider YouTube Channel and watch our episodes every week! Click here to subscribe.Links from the showGovee TV Backlight 3Govee G25 Filament BulbBose Lifestyle LineupBlu by ADTThose interested in sponsoring the show can reach out to us at: andrew@appleinsider.com

Jevan Lenox, Chief People Officer at Writer, joined us on The Modern People Leader. We talked about why AI adoption alone is not enough, how companies can use “directed innovation” to drive real business outcomes with AI, and what high performance looks like in the AI era.----  Sponsor Links:

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Javid Moslehi discusses managing the cardiovascular effects of ADT. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41539]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Javid Moslehi discusses managing the cardiovascular effects of ADT. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41539]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Javid Moslehi discusses managing the cardiovascular effects of ADT. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41539]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Michael Rabow discusses how to manage ADT-related adverse effects. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41538]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Michael Rabow discusses how to manage ADT-related adverse effects. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41538]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Michael Rabow discusses how to manage ADT-related adverse effects. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41538]

What if I told you that after focal therapy, a normal PSA and a clean MRI can still mean prostate cancer is hiding in plain sight?That's the moment in this conversation that makes you stop—and rethink everything you've been told about “success” after focal therapy.In this episode, we're joined by Abhinav Sidana, MD, MPH, Associate Professor of Urology and Director of Prostate Cancer at University of Chicago Medicine, a nationally recognized urologic oncologist, clinical trial leader, and one of the architects shaping the future of focal therapy. Dr. Sidana has trained at AIIMS, Johns Hopkins, NIH, and now leads one of the most rigorous focal therapy programs in the country—backed by over 100 peer-reviewed publications and multiple active clinical trials.This is not a sales pitch for focal therapy. It's a clear-eyed look at what works, what doesn't, and what we still get wrong.In this episode, you'll learn:✅ Why MRI made focal therapy possible—and why it can still miss clinically significant disease✅ How biopsy strategy—fusion, mapping, or transperineal—directly affects recurrence risk✅ Why PSA is an unreliable signal after focal therapy—and what actually predicts failure✅ How short-term ADT may expand focal therapy to larger or higher-risk tumorsIf you're a patient, clinician, or researcher navigating prostate cancer decisions, this episode will fundamentally sharpen how you think about focal therapy—and its limits.00:00 Can MRI and PSA Miss Significant Cancer After Focal Therapy?04:00 Who Is a Good Candidate for Focal Therapy?06:30 Mapping Biopsies vs MRI Fusion Biopsies09:30 Transperineal vs Transrectal Biopsies11:00 What Is IRE (NanoKnife)?14:30 Who Is NOT a Candidate for Focal Therapy?18:00 Vapor Therapy & TULSA Pro23:00 Should Doctors Use Multiple Focal Therapy Technologies?25:30 Can Higher-Risk Prostate Cancer Be Treated with Focal Therapy?34:00 Does the Type of Energy Matter?37:00 Combining ADT with Focal Therapy40:30 How Tumor Size Impacts Eligibility45:30 Why MRI and PSA Are Imperfect After Treatment49:30 What Is PSA Recurrence After Focal Therapy?53:30 The Future of MRI, AI, and Surveillance57:30 Do Patients Need Repeat Biopsies Forever?___________________________________

Two interesting papers caught the eye of our GU Cast China team this week; the first is the ARASEC trial which Dr Rana McKay read out in the Practice-Changing Plenary at the AUA Annual Meeting in Washington. This is an interesting comparison of ADT + darolutamide  for mHSPC in a prospective US cohort, compared with an historical ADT-only control arm from CHAARTED. Interesting study design and interesting results. The second is the ADT Lead-In study led bu GU Cast China Editor, Dr Yao Zhu, which demonstrates how the timing of docetaxel chemotherapy in mHSPC can significnatly affect the likelihood of severe neutropenia. Your usual hosts, Declan Murphy and Renu Eapen, anre joined by Dr Yao Zhu (Fudan University, Shanghai), Dr Yige Bau (SCU Xiamen), and Dr Chuguan Yang (Tonji Hospital, Wuhan). Yige now also part of our GU Cast China team, looking after our We Chat content with Yao Zhu. This is a Themed Podcast supported by our GU Cast China Partner, Bayer Pharmaceuticals.

Kirsten Moorefield, Chief Strategy Officer & Co-Founder at Cloverleaf, Sarika Lamont, CPO at Vidyard, and Sarah Royer, Sr. Manager of People Ops at Nirvana Insurance, joined us on The Modern People Leader for a live discussion on AI coaching. We talked about what AI coaching actually means today, building these tools in-house versus buying, and why career growth will never be a perfect checklist.----  Sponsor Links:

Cara Brennan Allamano (Founder of PeopleTech Partners and former Chief People Officer at Lattice) and Jevan Lenox (Chief People Officer at Writer) joined Stephen at Fix Healthcare Live. They talked about the growing pressure on HR leaders and why modern people leaders need to rethink how they operate in a rapidly changing world.----  Sponsor Links:

Lindsay Jurist-Rosner, Co-Founder and CEO of Wellthy, and Stephan Dolling, AVP of Global Benefits & Well-being at Merck, joined us on The Modern People Leader. We talked about the rising pressures facing working families and what companies can do to support their employees that are caregivers.----  Sponsor Links:

This week on TechRadio we've got some wild tech headlines — including GameStop's surprise $55+ billion bid to buy eBay! We also cover: The ADT data breach affecting up to 10 million customer records — what happened and what you should do Apple Vision Pro reportedly reaching the end of the line Important Gemini privacy settings you should check right now Nostalgic tech moment: Microsoft open-sources the original DOS 1.0 code Smart ways to stay safe online and our latest tops in streaming recommendations Whether you love big business drama, retro computing, privacy tips, or just want the week's tech stories explained clearly, this episode has something for everyone. Tune in for your friendly weekly tech update!  

Jessica Zwaan, VP People Strategy & Operations at Leapsome and author of Built For People, joined us for another MPL Build AMA. This time we talked about how to redesign your People team if you're running your team like a product team, why metrics like internal promotion retention matter more than traditional HR KPIs, and more.----  Sponsor Links:

See's Candies, Vimeo, Liberty Mutual Insurance, Carnival Cruises, Pitney Bowes, ADT and more are all part of this week's mess!

Amin Palizban, Co-Founder & CEO of TopicFlow, joined us on The Modern People Leader. We talked about why managers are at a breaking point, how AI is transforming performance management, and what it takes to build AI-native people products that actually support managers in real time.----  Get the AI for Performance Management Toolkit: https://modernpeopleleader.kit.com/aiforperformanceSponsor Links:

We discuss a couple of big stories from the week where insiders made a big profit on the prediction markets. We've discussed Polymarket and Kalshi before, but the concerns are going mainstream. We've also got some other tech news and tips to get caught up on, so you can get out there and tech better. Watch on YouTube! - Notnerd.com and Notpicks.com INTRO (00:00) Social Media Marketing World (02:20) AirPods - One backup is none backup (04:35) MAIN TOPIC: I wouldn't bet on that (07:20) France investigates suspected tampering with weather sensors after Polymarket bets DOJ arrests soldier who made $400,000 betting on Maduro's removal https://polymarket.com/ DAVE'S PRO-TIP OF THE WEEK: iOS Photos quick tools access (16:35) JUST THE HEADLINES: (21:05) Fans angry over Pokemon Go champion's disqualification for allegedly shaking the table Study finds a third of new websites are AI-generated Mozilla uses Anthropic's Mythos to fix 271 bugs in Firefox Home security giant ADT data breach affects 5.5 million people Ping-pong robot Ace makes history by beating top-level human players BMW is one step closer to selling you a color-changing car America now has 70% more bookstores than in 2020, says bookshop.org founder TAKES: China blocks Meta's $2 billion takeover of AI startup Manus (24:20) 20,000 job cuts at Meta, Microsoft raise concern that AI-driven labor crisis is here (28:45) BONUS ODD TAKE: Livestream of the Big Bear bald eagle nest (31:40)

ADT says customer data stolen in cyberattack SMS blasting comes to Toronto Researchers find pre-Stuxnet malware targeting engineering software Get the show notes here: https://cisoseries.com/cybersecurity-news-adt-data-breach-toronto-sms-blasting-pre-stuxnet-malware-discovery/ Thanks to our episode sponsor, Guardsquare Mobile app security isn't just a tech issue; it's a revenue issue. A recent global study found that seventy-two percent of organizations experienced a mobile app security incident last year. Even worse? Sixty-five percent saw customer churn or uninstalls as a result. Protect your brand and your bottom line with layered mobile app protection. Learn more at Guardsquare.com.

James Seechurn, Author of ‘What Pay Costs' and ‘Nothing Left to Take Away', joined us on The Modern People Leader.We talked about why traditional “pay for performance” systems often fail—both because individual performance is hard to measure in knowledge work and because incentives don't actually drive better outcomes. We also explored a new definition of performance centered on innovation, and how companies can unlock it by creating the conditions of autonomy, competence, and relatedness instead of relying on compensation levers.---Sponsor Links:

Claude Silver, Chief Heart Officer at VaynerX, joined us on The Modern People Leader. We talked about why workplace dread is increasing in today's environment, what Claude has learned from Gen Z employees, and how leaders can leave their “heart print” on the people they work with.----  Sponsor Links:

Zachary Parris, who's re-imagining talent development for the AI era at Google, joined us on The Modern People Leader. We talked about how AI is turning HR leaders into builders, why product thinking is replacing traditional HR programs, and how anyone can now create impactful tools without a technical background. ----  Sponsor Links:

Deborah Yount, CHRO at Sutter Health, joined us on The Modern People Leader to share her journey from finance to leading HR at one of the largest healthcare systems in the U.S. We discussed how Sutter reduced turnover by nearly 40%, built a culture of leadership accountability, and scaled employee experience and development across 60,000+ employees.----  Sponsor Links:

Eva Majercsik (Chief People Officer) and Trevor Schulze (CIO) at Genesys joined us on The Modern People Leader. We talked about how AI is reshaping how humans and machines work together, why CIO and CPO partnerships are more important than ever, and how to lead a human-centered AI transformation across the organization. ----  Sponsor Links:

We're back for more listener dating dilemmas, and we cover everything. From texting gaps and gut feelings, to dating with kids (and narcissistic exes), intentional dating vs. playing it cool, and how to show interest without overdoing it.We also get into independent women being punished for their independence, overbearing moms, men trashing their exes, co-parenting with narcissists, and how to keep your nervous system regulated when dating (or divorce) dynamics get messy. Plus, dating your husband when you have kids, setting boundaries, and trusting patterns when someone shows you exactly who they are.A word from my sponsors:Upward - Download Upward. The dating app where faith and values meet.ADT - When every second counts, count on ADT. Visit adt.com or call 1-800-ADT-ASAP.Figs - Get 15% off your first order at wearfigs.com with the code FIGSRXLMNT - Right now LMNT is offering a free sample pack with any purchase, That's 8 single serving packets FREE with any LMNT order. This is a great way to try all 8 flavors or share LMNT with a friend. Get yours at DrinkLMNT.com/HONEST.Kahlua - Find Kahlúa Dunkin Caramel Swirl at retailers nationwide, including Walmart, Total Wine, Albertsons, Kroger, Ralphs, Safeway, BevMo, Publix, and more. Must be 21 or older to purchase. Please drink responsibly.IQBAR - Text HONEST to 64000 to get 20% off all IQBAR products, plus FREE shipping. Message and data rates may apply.Taylor Farms - Grab a Taylor Farms chopped salad kit. And get your salad together!For more Let's Be Honest, follow along at:@kristincavallari on Instagram@kristincavallari and @dearmedia on TikTokLet's Be Honest with Kristin Cavallari on YouTubeProduced by Dear Media.This episode may contain paid endorsements and advertisements for products and services. Individuals on the show may have a direct or indirect financial interest in products, or services referred to in this episode.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Amit Rapaport, Co-Founder & CEO of Compete, joined us on The Modern People Leader. We talked about why most HR metrics don't matter to your CEO, how to think like a CEO when looking at workforce data, and more.----  Downloadable PDF with top takeaways: https://modernpeopleleader.kit.com/5-hr-rulesSponsor Links:

Deb (00:03.606)Within the next seven months, up to 1.5 million Americans could lose access to a medication that they’ve relied on for decades. Not because it’s dangerous, but because a pharmaceutical giant may have lobbied the FDA to eliminate their competition. And if you’re one of them, your doctor may already have told you about this issue and stopped prescribing it.This isn’t a conspiracy theory. This is documented in federal court filings. This is happening right now. And the company that stands to profit, well, they’re the same ones manufacturing the only product that might survive.Today on Let’s Talk Wellness Now, we’re exposing the desiccated thyroid extract crisis, the corporate manipulation behind it, and what you need to do right now to protect your health. Stay with me because I’m about to share what could save your access to the medication keeping you alive.Welcome back to Let’s Talk Wellness Now, the show where we uncover the root causes of chronic illness, expose regulatory capture in healthcare, and empower you with the tools to advocate for yourself. I’m Dr. Deb, naturopathic doctor, your medical detective, and today we’re diving into one of the most consequential and corrupt healthcare decisions affecting patients right now. If you or someone you love takes Armour thyroid, NP thyroid, or any desiccated thyroid extract,for hypothyroidism or if you’ve struggled to find a thyroid medication that actually works for your body, this episode is absolutely critical. And if you have celiac disease, gluten sensitivity or corn allergies, what I’m about to reveal will make your blood boil. Now grab your cup of coffee, don’t forget your notebook and settle in because what’s happening to this medication right now is a masterclass in how pharmaceutical companies use regular Deb (02:06.544)agencies to eliminate competition, control markets, and price gouge patients. And I have all the receipts. Deb (02:20.982)Let me start with what might surprise you. Desiccated thyroid extract, or DTE as we call it, is actually one of the most oldest thyroid medications in the world. And I mean old. From the 1890s through 1970, this was the standard treatment for hypothyroidism.Now let’s really dive into that. From the 1890s to the 1970s, this was standard hypothyroidism treatment.In 1965 alone, and this is documented in peer-reviewed literature published in the Journal of Clinical Endocrinology and Metabolism, approximately four out of every five prescriptions for thyroid hormone in the United States were of natural desiccated thyroid preparations.The Journal of Clinical Endocrinology and Metabolism is a very high-end journal. Now think about that. This wasn’t some fringe therapy. This was mainstream medicine. Armour Thyroid, the most recognizable brand name, has been manufactured since the early 1900s, well over a century ago.and this is cited again in NIH bookshelf. When the FDA was officially established in 1938, Arbor thyroid was already on the market. And this is important and I want you to understand why. Under the federal Food, Drug and Cosmetic Act, any drug that was already being marketed before 1938 was automatically grandfathered into the system. That means it didn’t have to Deb (04:08.112)go through the formal FDA approval process. And this again is cited under the Federal Food, Drug and Cosmetic Act, grandfathered drugs and exemptions. And this is crucial to understanding what happens next. By the 1970s, synthetic levothyroxine, brand name Synthroid and generics became the preferred treatment. Hmm, wonder why?It was easier to standardize, came into consistent doses, and worked well for most patients, and could be mass manufactured. By the 1980s, levothyroxine had largely replaced desiccated thyroid in clinical practice, according to the American Thyroid Association 2014 guidelines for the treatment of hypothyroidism. But here’s what matters. Some patients…a very significant minority of them, never felt right on levothyroxine alone. Despite their lab work looking normal, they still had fatigue, brain fog, weight gain, cold intolerance, and depression.These patients often found relief when they switched back to their desiccated thyroid, which contains both T4 and T3 hormones, the way human thyroid naturally produces them. And this is not anecdotal. This is documented in randomized double-blind crossover studies published in Endocrine Practice.For decades, that was fine. Their doctors prescribed it, insurance sometimes covered it, patients were getting better, and the system worked really well. Until August 6th of 2025, just a short time ago, everything changed. On that date, the FDA sent letters to manufacturers, importers, and distributors of desiccated thyroid extract products stating that these medications would need an approval. Deb (06:04.654)a biologics licensed application, a BLA, to remain legally on the market. And this is cited in the FDA’s official statement, FDA’s actions to address unapproved thyroid medications. understand it says unapproved thyroid medications. However, desiccated thyroid, specifically Armour, has been approved since 1938. And this was dated August 6th through 7th, 2025.This wasn’t a guideline. This wasn’t a suggestion. It was an endorsement of action. And the timeline they gave them? Well, just 12 months to transition patients to another medication before enforcement action could begin.This was also cited by an FDA notice to the industry, animal derived thyroid products notice to industry, August 6th, 2025. Now do the math, that means August 2026, seven months from now, 1.5 million Americans currently taking this medication. And this number comes from the FDA official statement, citing that it’s an estimation of 1.5 million patients receiving prescriptions for these medications.could potentially lose their thyroid access. Now, here’s where it gets interesting. The FDA didn’t wake up in August of 2025 and decide to regulate desiccated thyroid after a century. This decision has a much longer backstory. And understanding that backstory is critical to understanding what’s really happening in this industry.The shift started in 2022. Back in September of 2022, over three years ago, an FDA branch chief sent a letter to the National Associations of Boards of Pharmacy noting that the agency had decided to designate DTE as a biological product, which would affect its eligibility for compounding. Deb (08:13.972)This also is cited in an FDA letter to the National Association of Boards of Pharmacy September 2022.Then two months later, in November of 2022, the FDA’s Office of Compounding Quality and Compliance sent a softer letter acknowledging that many Americans take medication to treat hypothyroidism and some choose to take DTE products. The letter stated that the FDA would focus enforcement on cases that pose the greatest public health risks, such as serious adverse offense or serious product quality or adulteration.also is cited by an FDA letter from Francis G. Bromel, the director, Office of Compounding Quality and Compliance, November of 2022. Now, let me just think about this for a second. If this drug has been on the market since the 1800s, been FDA approved since 1938, would we not have seen a health crisis long before 2022?I honestly don’t know of any other drug that’s been around this long that’s used by this many people. Now granted, I haven’t done the research on it either, which I can do for you guys, but I’m just thinking if a drug is on the market today and it causes harm, it doesn’t make it three years, five years before you see lawsuits everywhere. Why are there no lawsuits on this drug? Why are there no major reactions that people are seen having?Hmm, just thought. But here’s the pattern. The FDA was already laying the groundwork back in 2022, testing the waters, signaling where this was headed. The August 2025 action. Then this came down. Deb (10:09.806)August 6, 2025, the FDA announced its position publicly and sent formal letters to all DTE manufacturers, importers, and distributors. This was cited by the FDA Enforcement Action August 6, 2025, letters to manufacturers, importers, distributions of DTE products. The agency stated several concerns. First, DTE products have experienced quality and dosing issues.The FDA cited, and I’m quoting directly from their statement, over 500 adverse events reported associated with DTE products from 1968 to 2025. From 1968 to 2025, we had 500 adverse reactions? What is that math equate to?A couple a year? Come on guys, this is insane! With a substantial increase, you, between 2019 and 2020 that the agency suggested was related to voluntary recalls of sub-potent or super-potent products.This was cited in the FDA statement, over 500 adverse events reported associated with ADT products from 1968 through 2025.Second, the agency expressed concern about batch inconsistency. According to the FDA’s official statements, tablets made from the same manufacturing batches may not always provide the same thyroid hormone levels. Okay, this was cited in the FDA statement, tablets made from the same manufacturing batches may not always provide the same thyroid hormone levels. Thirdly, and I want to actually let’s back up. I want you to remember I said that Deb (12:11.216)because further down in this podcast, we’re going to talk about this. This is an important point to remember. Thirdly, the agency raised concerns about potential impurities from animal source material, including potential for viral contamination due to the animal source and supraphysiological levels of T3.the FDA statement on impurities, viral contamination and super physiological T3 levels. Now I will tell you, I’ve been prescribing armarithograde for 20 years. I’ve rarely seen a super physiological dose given of T3 in lab results, unless the patient takes their medication like four or five hours before you do the blood test, then you’ll see a false rise because you’re actually seeing the medication. You’re not seeing people walking aroundsuperphysiological T3 levels. Nobody would like that feeling. So anyway, I digress. Now let me pause here because this is where I need to give you some context that the FDA hasn’t quite emphasized yet. Of course, we have another connection and it is the China connection.So the FDA’s concerns about contaminated drugs and quality issues don’t exist in a vacuum. In 2024, the U.S. over 828,000 metric tons of pharmaceuticals, seven times the level from 2000. And here’s the kicker. China and India supply the majority of active pharmaceutical ingredients. APIs for U.S. generics accounting for 70 to 80 % of the total genericdrug supply. According to Reuters industry report in 2024, they state that China supplies 82 % of the APIs for critical drugs. Deb (14:08.204)Got to question that, right? Why are we giving all of our drug formulas to China and allowing them to import them into our country? In fact, roughly 20 % of the critical drugs have APIs exclusively sourced from China. And China controls 80 to 90 % of the global production for antibiotics and other key compounds. This was also cited by Reuters industry data thatcontrols 80 to 90 percent of the global production for antibiotics and other key compounds. Now just think about this. They control 80 to 90 percent of our medication. They control 20 percent of our critical drugs and we just put what kind of tariff on them? Hmm.In 2025 alone, the FDA issued multiple warning letters to foreign manufacturers for contamination issues and failure to follow good manufacturing practices. This is also cited by the FDA warning letters 2024 through 2025 and multiple citations to foreign manufacturing facilities. This is a systematic problem affecting the entire US drug supply, not just desiccated thyroid.So when the FDA suddenly became concerned about DTE quality and contamination, part of that concern was legitimate. But this is crucial. The same inconsistencies and contamination issues exist across the entire generic drug supply. And the FDA has not taken the same enforcement action against them. Let that sink in.They have not taken the same enforcement action against the other drug companies. So what’s behind all of this? Where is this all coming from? Hmm. Let’s address something directly, because you deserve to know it. And I’m going to cite my sources precisely so that when the medical boards have something to say about this, and they might, I have a documentation for every single word that I am about to speak. Deb (16:24.878)According to the court documents filed in October 2025, in the case ofa urine, a urine. I’m going to say that wrong. Pharmaceuticals versus Dr. George Tidmarsh from ABBV, the multinational pharmaceutical company that manufactures armor thyroid, reportedly petitioned the FDA in 2024, asking the agency to reclassify DTE as a biologic and to prohibit other manufacturers from selling unlicensed DTE products unless they havehad an investigational new drug application, we call this an IND, and a clinical development program aimed at eventual approval. This is cited in the court filing a Urena pharmaceuticals lawsuit versus Dr. George Tidmarsh, October 2025, reported by Fierce Pharma. Now let me explain why this matters and why this is one of the most brazen examples of regulatory capture I’ve ever seen in my career.AbbeVee is one of the world’s largest pharmaceutical companies. In 2024, they reported over $54 billion in revenue. Drop the mic on that one.They have the resources, the regulatory expertise, the legal teams, and the financial capacity to navigate a biologics license application process that costs between $500 million and $1 billion. Let that sink in. Deb (18:07.882)A drug that’s been on the market since the 1800s that was grandfathered in 1938 that’s making plenty of money right now. They’re going to spend 500 million to $1 billion to get a biologics license application. Why would they do that? Well, we’re about to find out. Most otherDTE manufacturers, smaller companies like Acela Pharmaceuticals, which makes NP-thyroid, and RLC Labs, which made WP-thyroid, do not have those same resources. And this is cited in Pharma Voice in 2025. Why a treatment older than the FDA is getting new regulatory scrutiny. So when you petition the FDA to reclassify a drug in a way that requires this type of expensivetime-consuming biological approval, you’re not just asking for safety. You’re asking to eliminate your competitors from the marketplace. Now, I want to be very precise here. These allegations are documented in federal court filings, and it hasn’t been approved in court. It’s also been reported by multiple industry sources, including Fierce Pharma. But I’m telling you,what has been reported in legal proceedings, not stating it as an absolute fact because you deserve to know the difference and because I have to protect my license. Now, what do we know for certain?AbbeVee is working on a biologics license application for Armour thyroid through clinical trials called Avantia. This is cited by the AbbeVee corporate statement 2025 Avantia clinical trial for Armour thyroid. A cell of pharmaceuticals has been pursuing BLA approval for NP thyroid for seven years since 2017 and it completed its phase two trials successfully in 2025. They’re now moving Deb (20:15.448)into Phase 3 trials. This is also cited by the Acela Pharmaceuticals CEO statement 2025 seven-year pursuit for BLA approval completed Phase 2 trials moving to Phase 3.RLC Labs, which manufactured WP thyroid, has made no public announcement about pursuing BLA approval and really probably don’t have a plan to do this since they’ve been off the market for some time now. About five years, I think maybe a little longer. Here’s the market manipulation.If only ABBV is successful and obtains a BLA approval for Armour thyroid, that company would effectively have a monopoly on the DDT market. And in pharmaceutical markets, monopolies historically lead to price increases.We’ve seen this pattern over and over again when turning pharmaceuticals acquired Daraprim and raised their price from $13.50 to $750 per tablet overnight. When Myelin raised EpiPen increased prices by 400 % when insulin manufacturers colluded to raise prices in lockstep. This is the playbook.use regulatory barriers to eliminate your competition and then exploit pricing power. For a drug that’s been on the market since the 1800s, guess corporate greed is everywhere. They’re not making enough money on this product already and they’re taking advantage of the rules that they can manipulate their competition by. And here’s what really makes me furious. The American Thyroid Association, the professional organization Deb (22:06.672)representing endocrinologists sent letters to the FDA commissioner on October 8th of 2025 and September 18th of 2025.advocating for continued patient access to DTEs. This is cited in the American Thyroid Association statement and letter to the FDA commissioner dated October 8th, 2025 and September 18th, 2025. The American Association of Clinical Endocrinologists issued a statement on September 9th of 2025 supporting equitable access and personalized medicine for DTE. This was also cited in the American AssociationAssociation of Clinical Endocrinologists, AACE, statement dated September 9th, 2025. Even the medical establishment, which has historically favored levothyroxine, is saying, wait, this is going too far. Patients need access to this medication. But the FDA is moving forward anyway. Why? Well, where does it always lead us? Follow the money trail.Okay, so I need to explain what a biologics license application actually is because this is where the rubber meets the road for what’s going to happen to pricing and availability. What is a BLA?A BLA is a biologics license application. It’s a formal request submitted to the FDA to market a biologic product in the United States. A biologic is defined under the Public Health Service Act section 351 as a product derived from or made using living material, in this case, animal thyroid glands. And this is cited in the FDA definition for biologic products. So they’re putting armor thyroid right Deb (23:57.377)right up with stem cells and exosomes. Think about that. Stem cells and exosomes cost thousands of dollars per application because of how they have to be harvested, stored, freezed, all of that. But we’re talking about a thyroid gland. Good Lord, people.Unlike regular drug applications for synthetic medications which follow a simpler pathway, the BLA process is designed for complex biological products like monoclonal antibodies, vaccines, and gene therapy products. It’s a much more expensive, much more time-consuming process. The BLA processis what manufacturers have to do. And we’re going to talk about that. So according to Reprocell and Forge Biologics analysis of the FDA’s BLA process, here’s what companies need to submit. First, they need to complete a clinical trial data, phase one, two, and three trials, proving safety and efficacy for desiccated thyroid. Haven’t we done that since it’s been on the market since the 1800s? Just saying.This means they have to conduct large randomized controlled trials comparing it to levothyroxine, measuring safety outcomes, efficacy outcomes, and quality of life metrics. Second,Chemistry, Manufacturing and Controls, CMC’s data. Detailed information about how the product is manufactured, quality control measures, stability testing and specifications that must be met for every batch. Third, preclinical and animal safety data. Fourth, labeling and product information. Now, I think we have labeling and product information. Deb (25:53.717)since the 1800s? But just saying. Fifth, they need Pharma Covigilance Plan, a detailed plan for monitoring safety after the product is on the market. Haven’t they had to do that since the 1800s? And they have to have a timeline. And this is the critical part. The FDA’s standard review time for a BLA is 10 months.That’s after the application is deemed complete and accepted for filing. So this is cited by the FDA standard review timeline, BLA submission, and FDA review.Now, before you even get to filing, you need to conduct the clinical trials and compile all the data that’s typically several years of work. How are you going to prove safety and effectiveness in a large clinical trial long term? What do they consider? What do they deem long term? Three months, six months, a year, two years. These companies had 10 months.Well, maybe 12. They did it a year in advance. But unless you knew this was coming, how are you going to put together a trial, enroll the people, have all the trial components set up and ready to go in less than 12 months unless you knew it was coming beforehand? Even ifhad started all their clinical trials in 2024, completing them, compiling the data, and getting a complete application ready for submission, this would likely take you through mid-2026, then add another 10 months for FDA review. We’re looking at 2027 at the earliest for most of these companies to receive a BLA application. Deb (27:54.319)But the FDA gave the manufacturers until August of 2026. That’s approximately 19 months from when the August 2025 letters were sent. Most companies cannot reasonably complete the BLA approval in that timeframe. And when I’m talking about the 19 months, I’m talking about the information they would have had earlier. Now the cost.This gets me even more frustrated. Why are we spending this kind of money? The BLL process is extraordinarily expensive. The current FDA user fee for a BLA submission is approximately $483,560 just for the filing fee. And this is cited at the FDA user fees prescription drug user fee rates for 2025.The full cost of conducting clinical trials, CMC studies, and all the supporting documentation typically ranges from $500 million to over $1 billion, depending on the scope of the trials and the complexity. And this is cited in JAMA’s network, Open2023. A cell of pharmaceuticals has been pursuing the BLA approval since 2017. That’s eight years. And it’s just now.moving into phase three trials with a planned enrollment of approximately 300 patients. This is cited by the Acela Pharmacies CEO statement of 2025. Now that’s unusual. That’s typical for this process. This is not unusual. This is typical for this process to take seven, 10 years to get approval for this. So if Abby’s the one that requested this,Abby V. And Acela started this in 2017. Was Abby V threatened by Acela that Acela might get this approval and it would be quietly done without anybody seeing it? And maybe Abby V would be left out of the market after a century? Who knows? It’s possible. Deb (30:13.112)But for smaller manufacturers without billions in revenue, this cost is completely prohibitive. And this is why this matters. When you push an old established medication through an extraordinary, expensive approval process with a compromised timeline, one of three things happen. First, only the largest companies can afford it, creating a monopoly. And when that happens, the company that holds the only approved product can set pricing withminimal competitive pressures. Two, smaller manufacturers can’t afford it and their products disappear and the market shrinks and access decreases. Three, we see a combination of both and who pays the price? Literally, patients do. Now here’s whereThere’s something I want you to really think about because this is where the regulatory argument falls apart when you look at it carefully. The FDA’s concern about DTE is that, and I’m quoting their official statement, tablets from the same manufacturing batches may not always provide the same thyroid hormone levels. This is from their FDA statement.And that’s a legitimate quality concern, right? It is. Thyroid medications have a narrow therapeutic window like any other hormone, meaning the difference between an effective dose and the dose that causes problems can be quite small. But here’s what the FDA doesn’t emphasize. Generic drugs have the exact same dosing inconsistency issue, and it’s considered acceptable and has been since we allowed generics on the market.So how does a generic drug dose work anyway? Well, for generic drugs to be approved as bioequivalent to a brand name medication, the FDA requires that the generic drugs bioavailability fall within 80 to 125 % of the brand name product. Isn’t that a dose inconsistency? Deb (32:22.894)from the brand name medication? 800 or sorry, 80 to 125%. According to the pharmacy times analysis of the FDA’s bioequivalent standards, the 80 to 125 % bioequivalence rule means that a generic drug can have 20 to 45 % variability compared to the original brand product.Now, most generics are much closer than that. The FDA study data shows that the mean difference for an AUC value between generic and reference products is about three and a half percent in the two year post-Waxman hatch period, and 80 % of the generics fall within a five percent range. But the FDA’s regulations allow for that much higher variability. And this is cited in an FDA study data mean difference for AUC.Now, let me put this in plain language. A patient could take a generic levothyroxine tablet where one batch provides, say, 75 micrograms of an active thyroid hormone. And the next batch from a different manufacturer, a different generic manufacturer, could provide up to 93.75 micrograms, 125 % of that 75. That’s an 18 microgram difference.in the same prescribed dose. Now, this is considered acceptable and patients tolerate it and this system works.Yet the FDA’s argument against DTE is that batch-to-batch inconsistency is unacceptable and requires this expensive biologic approval? That’s a double standard. So why is batch inconsistency acceptable for generic levothyroxine, but supposedly unacceptable for desiccated thyroid? I’ll give you the regulatory answer. Deb (34:29.366)because DDT is a biological product derived from an animal tissue and the FDA considers biological products to require more rigorous control. That’s the regulatory answer, but I’ll give you the real answer.because there’s no billion dollar pharmaceutical company with a patent pending on generic levothyroxine who petitioned the FDA to regulate their competitors more strictly. The inconsistency argument is legitimate, but it’s selectively applied. And that matters when you’re trying to understand whether this is really about patient safety or whether it’s about market control.Now I want to talk about something that hasn’t gotten nearly enough attention in this discussion and it’s something that makes me absolutely furious. What is Armour Thyroid? According to the official prescribing information published by AbbeV and available through rxabbev.com and the FDA’s daily med database, Armour Thyroid contains the following inactive ingredients. Calcium steroid,dextrose derived from corn, mycocrystalline cellulose,sodium starch glycolate and a opadri white coating. Now let’s talk about dextrose. Dextrose is a sugar derived from corn and while manufacturers claim that the corn derived dextrose in armor thyroid is gluten free, here’s the problem. Cross contamination during corn processing can introduce gluten proteins especially if the corn is processed in facilities that also handle Deb (36:18.808)wheat, barley, or rye. Corn sensitivity is extremely common in patients with celiac disease and non-celiac gluten sensitivity, and studies show that up to 50 % of the celiac patients react to corn proteins due to molecular mimicry, and the corn proteins look similar enough to gluten that the immune system attacks them. And this is cited by RestartMD.com.And here’s what’s documented in peer-reviewed medical literature in a 2023 case report published in Case Reports in Endocrinology. These researchers documented five patients with gluten intolerance or celiac who were taking natural desiccated thyroid. Three of those patients also reported lactose intolerance. Now these patients had to switch from DTE to liquid levothyroxine formulations to avoid the inactiveSo here’s my question. If AbbeV becomes the only manufacturer with an approved DTE product and their formulations contain corn-derived dextrose that triggers reactions in celiac patients, what are those patients supposed to do? They can’t take armor because of the corn. They can’t take compounded DTE because the FDA is banning compounding of these biologics. They can’t take NPKsor WP thyroid because those companies may not survive the BLA process. So they’re left with a synthetic version of levothyroxine which may not work for them.Now the NP thyroid and WP thyroid difference. Now here’s what’s interesting according to drugs.com comparison of inactive ingredients and P thyroid and P thyroid has calcium steroid dextrose also derived from corn, mineral oil, multi-crystalline cellulose. Deb (38:19.31)cross carmelicin sodium and a opadri to white. So NP thyroid also has corn-derived dextrose. WP thyroid on the other hand was specifically formulated to be hypoallergenic according to ROC labs, but it’s no longer available and its ingredients were inulin from chicory root and medium chain triglycerides. No corn, no gluten, no common allergies. So todayWe do not have a glandular thyroid, a DTE, that is not potentially contaminated with gluten. Yet, patients with autoimmune thyroid disease are supposed to avoid gluten.Now, some of these people can handle a DTE and many cannot, so that argument could be a mute point. But at the end of the day, the one product that we had that was designated for patients with multiple chemical sensitivities, celiac disease and coron allergies, has been off the market for a long time already.We have a monopoly problem. So if ABBV becomes the only approved manufacturer, patients with these celiac diseases and corn allergies will either be forced to take a medicine that makes them sick and triggers their immune reaction or switch to a synthetic that doesn’t adequately treat their hypothyroidism or choose to go without treatment. This is not hypothetical. This is real patients with real medical needs who are about to lose accessto the only formulation that works for their body. And the FDA’s response is silence. Deb (40:07.69)Now I want to highlight something that hasn’t gotten nearly enough attention in this discussion. Compounding pharmacies. What is a compounding pharmacy? Compounded medications are custom made by licensed pharmacists to meet a patient’s specific needs. Maybe you need a different strength that was commercially available, but you have an allergy to a filler or a dye in the commercial product. Maybe you need a liquid formulation or instead of a tablet or you need a capsule. That’s when compoundingin. And the FDA’s, this is the FDA’s definition of compounding. And for decades, compounding pharmacies have been making desiccated thyroid extract for patients who needed customization. Some patients couldn’t take the commercial products because of the dyes and the fillers, and some needed strengths that were not available. And these compounding pharmacies filled the gap.But reclassification changes everything. When the FDA reclassified DTE as a biologic in 2022 and reinforced that decision in August of 2025, explicitly stated, and I’m quoting directly from the FDA’s official statement, these unapproved animal-derived thyroid medications are not eligible for compounding because these products are regulated as biologic products under the Public Health Service Act.How can that be? These products have been approved since 1938 and the Biologics Act didn’t go into effect or doesn’t go into effect until August of 2026.So how in 2022 were they able to say that the compounding pharmacies could not make these products? Anyway, what this means is after August 2026, compounding pharmacies will no longer be permitted to compound a desiccated thyroid extract, even for patients with specific medical needs. Now, compounding pharmacies can still compound T4 and T3 separately, synthetic versions of levothyroxine and liothyronine, according to Deb (42:12.728)healing dose compounding pharmacy. These pharmacists can create custom ratios of these two synthetic hormones to approximate what a patient was receiving from a DTE. But that’s not the same thing. Some patients respond better to the whole DTE preparation than to a compounded synthetic combination. And for patients with specific allergies to standard fillers like your celiac patients that I just talked about, losing the ability to get a compounded DTE alternative isreal hardship. This is going to be a ripple effect. For a subset of patients, maybe 5 to 10 percent of those on DTE compounding was their lifeline and it was their way to get a medication formulation that worked for their unique body. When compounding goes away, these patients lose that option as well and for some it will be a significant problem. Now let’s talk about what this likely means for your wallet.The current pricing right now, according to SingleCare and GoodRx, Armour Thyroid costs approximately $150 to $157 for a 90-day supply of 60-milligram tablets, about $1.67 per tablet. With discount cards, some patients can get it down to $101 to $152 for a 90-day supply.Generic levon thyroxine costs about $70 for a 90 day supply, less than half that price. And p-thyroid costs approximately $133 for a 90 day supply of 60 milligrams with a discount card about $83 to $101.What happens after we get BLA approval? Well, here’s the pharmaceuticals pricing model. When a company spends 500 million to $1 billion to bring a product to market, including conducting massive clinical trials, the cost tens of millions of dollars they recoup in that investment through pricing power. And this is cited in the pharmaceutical pricing models. If ABBIEV is the only company with an approved BLA of DTE, Deb (44:18.248)They have pricing power. They don’t have competitors. They can set their price, whatever they want. And historically, when drugs transition from grandfather status, which is basically unregulated to formal formally approved status, prices often increase significantly, not always, but often. And typically they have to get re-approval for insurance. SoTouring Pharmaceuticals acquired DARPM and raised the price again from $1,350 to $750 overnight, a 5,000 % increase. This is the playbook.Let’s talk about insurance coverage. This is the other consideration. Insurance companies sometimes have different coverage policies for approved versions versus unapproved drugs. And right now, many insurance plans cover armor thyroid or NP thyroid, even though they’re technically unapproved because they’ve been on the market for decades and patients are on them. Once a drug becomes formally approved, insurance companies may have new contractual relationships, prior authorization requirements, or preferred drugs.list that could affect your coverage. If 1.5 million people have to get a prior auth for their insurance to cover this new medication, this is going to drive the doctor’s offices crazy. We do not have the staff to man this. We do not have the manpower. We do not have the time. This is going to interrupt people’s ability to get their medications. This is going to create chaos within the system. And some patients might see better coverage, but manymost likely are going to see worse coverage and some might find themselves in a situation where they need to try to get the drug approved first or get an approval for something else like levothyroxine and they’re going to have to document that it didn’t work and the documentation that they had from 20 years ago is probably not going to be enough because it’s not documented anywhere. It’s lost in the system after 10 years. So for patients the practical takeaway is expect Deb (46:25.774)a price increase. I would say possible, but I don’t think that’s true. think you’re going to see a price increase if they get approved. Expect possible insurance complexities, budget accordingly, talk to your insurance company now about what your coverage is going to look like in 2027 if they even know. And if you want my honest assessment of what is likely to happen,I’ll give you a scenario, 30 % likelihood. The FDA enforces the August 26 deadline and DTE products not approved by then are pulled from the market. Patients will have 30 to 90 days to transition to other medications. Some patients suffer significant symptom relapse. Compounding for DTE becomes illegal and this disruptiveness of the system creates a real hardship. Scenario two.which is 50 % likely. This is actually what the FDA commissioner, Marty McCreary suggested on August 13th of 2025 when he posted on social media. The FDA is committed to pursuing the first ever approval of desiccated thyroid access pending results of the ongoing clinical trials. In the meantime, we’ll ensure access for all Americans. Hopefully that continues. What this likely means is the FDA uses enforcement discretion to allow continuedsales while approvals are being pursued and the deadline gets extended. Maybe patients get access for another two to three years while companies work on a BLA approval. This would be the least disruptive scenario, but it’s also legally uncertain because the enforcement letters have been formally rescinded. And scenario three, which is 20 % likelihood, one or two companies get BLA approval. Those products stay on the market at higher product prices and companies, products, other companiescompanies, products are pulled, the market shrinks, availability is limited, prices are higher, but patients can still get something. This is likely if a seller successfully completes phase three trials for NP-thyroid. And my assessment is based on the regulatory language and the enforcement letters that have not been rescinded yet, that the pattern of FDA enforcement, I believe scenario two enforcement discretion with an extended time frame is most likely what we’re going to see. Deb (48:49.488)doesn’t mean patients should sit back and do nothing. It means you should be prepared for change while advocating for access. If you want to keep Arm or Thigh Right on the market, 1.5 million people need to start talking about this publicly and flooding our Congress people, Bobby Kennedy, the FDA, with what you want to see happen. We have the ability to shape this and to change this with our voice. But if we sit back on our laurels and we do absolutelynothing. What is going to happen is what the FDA wants to have happen and ABV wants to have happen because they’re going to simply think people don’t give a shit. And if the American people are going to be lazy and not want to step forward and actually start using their voice for some good and instead of just going to social media and bitching and hoping something is going to happen, well, then we’re going to get what we deserve. But if you start taking someaction and you start advocating for the things that you want. Contacting your representatives, contacting your U.S. tell them the FDA has done this. Many of them may not know this, may not be on their radar. Tell them what you want. Start going after this. Start writing to the FDA Commissioner’s Office. They have a website. They have a Commissioner’s Office at fda.hhs.gov. Be responsible.respectful, but be firm. Explain your scenario. How long you’ve been on DTE. Why levothyroxine doesn’t work. What symptoms you experience when not adequately treated. How this decision will affect your quality of life and your pocketbook. Let’s do something proactive. So let’s consider this. Moving forward, work with your provider who understands the regulatory landscape around DTE. You can discuss the evidence for and against combination therapy.You can monitor for thyroid function with free T3 and free T4 testing, not just TSH. If you’re willing to try individualized approaches, you can do that. If you need help finding a functional medicine provider who understands this issue, come to serenityhealthcarecenter.com or explorethevanari.com. It’s a self-directed functional medicine support group. And right now what is happening is going to shape how history Deb (51:19.024)is made with not just armor thyroid, but many drugs to come. And it is important for you to take action. So I want to thank you for joining me today on Let’s Talk Wellness Now. This episode is about far more than thyroid medication. It’s about your right to personalized medical treatment. It’s about your regulatory capture and corporate influence. And it’s about what happens when billion dollar companies shape healthcare policy in ways that reduce patient choice and increase their profits.this episode resonates with you or you know somebody who’s going to be affected by desiccated thyroid, please share it. Post it on social media, send it to your doctor, email it to your representatives, tag AbbeVee, tag FDA. Make noise because the only way we stop this is if we make it too politically costly for them to continue. Your voice truly matters. Your health truly matters and you deserve access to treatments that work best for your unique body.If you’re ready to explore comprehensive personalized health care that puts you in control, visit us at SerenityHealthCareCenter.com. Learn more about functional medicine approaches to thyroid and beyond and explore my new platform, Venari.com, which is a self-directed functional medicine tool. Thank you for joining me today. Until next time, I’m Dr. Deb reminding you, your health is your responsibility, your choice, and your right. Be well, stay informed, fight back.and I’ll see you in the next episode. And if you’re looking for a full citation list of this episode, you can head over to letstalkwellnessnow.com and I will post all the citations for you so you have them in your arsenal as well. Thank you again.The post Episode 259 – The Desiccated Thyroid Crisis: FDA's Unseen Impact & Corporate Manipulation first appeared on Let's Talk Wellness Now.

Beth Ley, Chief People Officer at Kendra Scott, joined us on The Modern People Leader. We talked about how to build the number one workplace for women, the “Great Talent Transfer” and Beth's vision for internal talent mobility, and what it's like to work with a visionary founder.---- Sponsor Links:

Listener dating dilemmas are back—and I'm always reminded how crazy it is out there. This episode is packed with your real-life dating questions, from men in relationships following (and liking) other women on social media, to ghosting, exclusivity gone wrong, and major red flags you should never ignore. We're talking social media behavior, emotional maturity, cheating in the honeymoon phase, and why liking photos is very different than just following.I also get into flirting (how to do it without overthinking), dating younger men, money in relationships, being “too loyal too fast,” and whether it's okay to have fun with the wrong ones while waiting for the right one. Plus, what it really means when someone won't talk about their past, why photos of an ex are an immediate no, and how to support a friend who keeps dating the same toxic type.A word from my sponsors:Nutrafol - See thicker, stronger, faster-growing hair with less shedding in just 3-6 months with Nutrafol. For a limited time, Nutrafol is offering our listeners $10 off your first month's subscription and free shipping when you go to Nutrafol.com and enter the promo code HONESTTaylor Farms - Grab a Taylor Farms chopped salad kit. And get your salad together!Upward - Download Upward. The dating app where faith and values meet.ADT - When every second counts, count on ADT. Visit adt.com or call 1-800-ADT-ASAP.Mill - Try Mill risk-free for 90 days and get $75 off at mill.com/HONEST and use code HONEST at checkout.Revolve - Shop at REVOLVE.com/HONEST and use code HONEST for 15% off your first order. #REVOLVEpartnerKahlua - Find Kahlúa Dunkin Caramel Swirl at retailers nationwide, including Walmart, Total Wine, Albertsons, Kroger, Ralphs, Safeway, BevMo, Publix, and more. Must be 21 or older to purchase. Please drink responsiblyFor more Let's Be Honest, follow along at:@kristincavallari on Instagram@kristincavallari and @dearmedia on TikTokLet's Be Honest with Kristin Cavallari on YouTubeProduced by Dear Media.This episode may contain paid endorsements and advertisements for products and services. Individuals on the show may have a direct or indirect financial interest in products, or services referred to in this episode.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Matt McFarlane, Founder of FNDN, joined us on The Modern People Leader. We talked about how to build a successful HR consulting business, why niching down and strong branding matter, and how to create sustainable growth through content, community, and a portfolio career.----  Sponsor Links:

Welcome to the Oncology Brothers podcast! In this episode, we discussed the current treatment landscape for prostate cancer, featuring special guest Dr. Scott Tagawa, a GU Medical Oncologist from Weill Cornell Medicine. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: X/Twitter: https://twitter.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Join us as we explored: The current standard of care for localized prostate cancer, including active surveillance, surgery, and radiation. The significance of ADT and abiraterone in high-risk disease, supported by the STAMPEDE trial. The role of PSMA PET/CT in staging and how it impacts treatment decisions. Treatment options for castration-sensitive and castration-resistant prostate cancer, including the use of ARPi and chemotherapy. The importance of germline and somatic testing, especially with the recent approval of Niraparib for BRCA2-positive disease. Insights on managing side effects and the nuances of patient-centered care in oncology. Whether you're a healthcare professional or someone interested in the latest advancements in cancer treatment, this episode is packed with valuable information to help you stay informed. Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers! #ProstateCancer, #ADT, #PSMA, #PARPinhibitor, #OncologyBrothers

Most benefits strategies fail for one simple reason: employees don't know how to use them. Matt Scovil, Co-Founder and CEO of Medefy, joined us to break down why confusing benefits lead to higher healthcare costs, why behavior change is the real unlock, and how HR teams can turn benefits from a cost center into something employees actually use.----  Downloadable PDF with top takeaways: https://modernpeopleleader.kit.com/episode288Sponsor Links:

This week, I'm joined by country music's most eligible bachelor, Tucker Wetmore. We talk about how a football injury changed the course of his life, what it was like moving to Nashville without knowing a single soul, and how one song completely flipped everything.A word from my sponsors:Netflix's Age of Attraction - Watch Age of Attraction Wednesdays starting March 11, only on NetflixTaylor Farms - Grab a Taylor Farms chopped salad kit. And get your salad together!ADT - When every second counts, count on ADT. Visit adt.com or call 1-800-ADT-ASAP.Bon Charge - Go to boncharge.com/HONEST and use coupon code HONEST to save 15%.Ritual - Save 25% on your first month at Ritual.com/BEHONESTFIGS - Get 15% off your first order at wearfigs.com with the code FIGSRXVivrelle - Go to www.vivrelle.com and apply for a membership today using referral code HONEST for your first month of membership free - the code will also allow you to skip the Vivrelle waitlist.For more Let's Be Honest, follow along at:@kristincavallari on Instagram@kristincavallari and @dearmedia on TikTokLet's Be Honest with Kristin Cavallari on YouTubeProduced by Dear Media.This episode may contain paid endorsements and advertisements for products and services. Individuals on the show may have a direct or indirect financial interest in products, or services referred to in this episode.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Alex Coonce (Chief People Officer) and Patrick Quigley (CEO) from Sidecar Health joined us on The Modern People Leader. We talked about building a strong CEO–CPO partnership, why culture must scale before headcount does, and how companies can become AI-native while staying transparent with employees.----  Downloadable PDF with top takeaways: https://modernpeopleleader.kit.com/episode287Sponsor Links:

If you've made the decision to get a divorce (or are about to), this episode is for you. I share the 10 things I wish someone had told me before, during, and after my own divorce — from consulting an attorney and protecting your finances, to handling your ex and navigating co-parenting, to taking care of your emotional and physical well-being.A word from my sponsors:Upward - Download Upward. The dating app where faith and values meet.ADT - When every second counts, count on ADT. Visit adt.com or call 1-800-ADT-ASAP.Taylor Farms - Grab a Taylor Farms chopped salad kit. And get your salad together!Hiya - Receive 50% off your first order. To claim this deal, you must go to hiyahealth.com/HONEST.IQBAR - Text HONEST to 64000 to get 20% off all IQBAR products, plus FREE shipping. Message and data rates may apply.Wayfair - Get last-minute hosting essentials, gifts for all your loved ones, and decor to celebrate the holidays for WAY less. Head to Wayfair.com right now to shop all things home.Netflix's Age of Attraction - Watch Age of Attraction Wednesdays starting March 11, only on NetflixFor more Let's Be Honest, follow along at:@kristincavallari on Instagram@kristincavallari and @dearmedia on TikTokLet's Be Honest with Kristin Cavallari on YouTubeProduced by Dear Media.This episode may contain paid endorsements and advertisements for products and services. Individuals on the show may have a direct or indirect financial interest in products, or services referred to in this episode.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.